#SCCT2024 will bring you 4 days of outstanding scientific sessions from world-class speakers, with an exhibit hall showcasing the latest #YesCCT technology. 👉 ow.ly/lub750QX2Yy

Regarding per-vessel prediction of FFR ≤ 0.8, AI-QCTISCHEMIA revealed greater specificity, PPV, accuracy, and AUC vs. CT-FFR and physician visual interpretation CADRADS ≥3. #EHJIMP academic.oup.com/ehjimp/arti… @JGrapsa @EZancanaroMD @SilCastelletti @Sarah_Moharem

Derivation and Validation of Cleerly ISCHEMIA. Congratulations to @NickNurmohamed, Ibrahim Danad, @AChoiHeart, Jim Min and @ARrosendael for their groundbreaking manuscript published recently in JACC Imaging (jacc.org/doi/10.1016/j.jcmg.…) #YesCCT

Atherosclerosis evaluation and cardiovascular risk estimation using coronary computed tomography angiography. A State-of-the-Art Review just published in #EHJ @escardio @ESC_Journals #CardioTwitter #atherosclerosis #CCTA @DLBHATTMD @NickNurmohamed academic.oup.com/eurheartj/a…

#ACCImaging great attendance!! @purviparwani @RonBlankstein @AChoiHeart @salernomdphd @ChrisKramerMD @MMukherjeeMD @ACCinTouch @mdicarli

We have an opening for a 2 year cardiovascular imaging fellowship starting July 2023. We are inviting applications for this opportunity. tinyurl.com/29uxypmz Year 1: Structural echo. We have one of the highest volume programs in the country. Year 2: Full spectrum MRT/CT.

#YesCCT ready for primetime: CAD-RADS 2.0 & beyond @AChoiHeart #CVImaging #ACC2023

AI-driven heart disease firm @cleerly_inc raises $192 million in Series C funding. CEO Dr. Jim Min tells me that raising cash has been tougher for health tech this year. "We were fortunate not only to realize our financing goals but also to enjoy an oversubscribed round."

Today, @FierceMedTech recognized @Cleerly_inc as one of 2021’s Fierce 15 Med Tech Companies! This celebrates our spirit of being “fierce” – championing innovation and creativity. Read more about Cleerly and this year’s winners here: fiercebiotech.com/special-re… #MedTech

Heart disease is the leading cause of death in the United States. That's why we led 14 Members in urging @CMSGov to cover the use of the cutting-edge CCTA test to detect coronary artery disease. Our letter #ICYMI:

Dr. Reynolds presenting quantitative plaque analysis from #ISCHEMIA by @cleerly_inc - total plaque burden strongest predictor of death/MI, incremental at 4 yrs f/u - in pts with advanced athero, obst CAD and ischemia. #YesCCT @Heart_SCCT @lesleejshaw @jayearls @RonBlankstein

New 2021 #CPGuideline - the presence of coronary atherosclerosis/non-obstructive is now part of CAD definition - one of the most important changes highlighted by @DrMarthaGulati #YesCCT @Heart_SCCT @AChoiHeart @RonBlankstein @MBittencourtMD @EricWillMD

Finally, CT angiography is the preferred test in US for a majority of patients with chest pain, following the UK (NICE) and ESC 2019 Guidelines. Great editorial by @RonBlankstein @DrMarthaGulati @lesleejshaw puts this in clinical perspective

Cor calcium/plaque in preventive cardiology #ACC21 Dr. Blankstein ☆ risk assessment by 🫀CT - intensive Rx given to highest risk ☆plaque burden not stenosis = main predictor of CV risk ☆⬇️attenuation/ remodelling/spot cal= ⬆️risk ☆ plaque imaging may ⬆️outcome @lesleejshaw

#Atherosclerosis: In this @journalCCT #review, by Lin FY, et al the authors review #CAD atherosclerosis imaging, plaque imaging and also future clinical and research implications in asymptomatic prevention, stable chest pain & acute chest pain #YesCCT bit.ly/2XjX5YE